Matches in SemOpenAlex for { <https://semopenalex.org/work/W2187738963> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2187738963 endingPage "75" @default.
- W2187738963 startingPage "1868" @default.
- W2187738963 abstract "The Code of Federal Regulations, title 10, part 35.75 (10CFR35.75), provides greater latitude and flexibility in the dosing and management of outpatients treated with therapeutic 131I than did preceding regulations. Prescribing physicians should consider applying these new regulations to enhance patient convenience and lower the cost of managing appropriate outpatients. Managed care organizations and third-party payers may require that all eligible patients be treated as outpatients or that justification for hospital admission be specifically documented. To facilitate application of the code and guidelines, maximum 131I doses for patients undergoing thyroid remnant ablation, therapy for metastatic or recurrent thyroid cancer, or therapy for hyperthyroidism have been calculated and summarized in tables.A model was developed that calculates the maximum dose of 131I that may be dispensed to an outpatient. This model complies with 10CFR35.75. The maximum dose is calculated as a function of 5 variables: the occupancy factors for 3 periods after dose administration, the fractional uptake of 131I by residual thyroid tissue or metastasis, and the duration of constrained activity. Occupancy factor, a key new concept in the regulatory guidelines, is a physician estimate of the time that a treated patient will be near the individual with whom the patient will spend the most time after treatment. The model also considers 3 constants: the effective half-life of 131I during the preequilibrium period, and the effective half-lives of 131I in both the thyroidal component and the extrathyroidal component during the equilibrium period. Tables for maximum allowable patient 131I doses were derived on the basis of this model.Through dosing charts, maximum 131I therapy doses may easily be calculated. Most outpatients undergoing thyroid remnant ablation, therapy for metastatic or recurrent thyroid cancer, or therapy for hyperthyroidism may be treated with 7400 MBq (200 mCi) 131I or more.If the prescribing physician understands the concept of occupancy factor and how to use the dosing charts, our model facilitates application of and adherence to 10CFR35.75." @default.
- W2187738963 created "2016-06-24" @default.
- W2187738963 creator A5010066811 @default.
- W2187738963 creator A5043001779 @default.
- W2187738963 creator A5050598747 @default.
- W2187738963 creator A5056712641 @default.
- W2187738963 date "2000-11-01" @default.
- W2187738963 modified "2023-09-23" @default.
- W2187738963 title "Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75." @default.
- W2187738963 cites W1504604090 @default.
- W2187738963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11079497" @default.
- W2187738963 hasPublicationYear "2000" @default.
- W2187738963 type Work @default.
- W2187738963 sameAs 2187738963 @default.
- W2187738963 citedByCount "12" @default.
- W2187738963 countsByYear W21877389632013 @default.
- W2187738963 countsByYear W21877389632014 @default.
- W2187738963 countsByYear W21877389632015 @default.
- W2187738963 crossrefType "journal-article" @default.
- W2187738963 hasAuthorship W2187738963A5010066811 @default.
- W2187738963 hasAuthorship W2187738963A5043001779 @default.
- W2187738963 hasAuthorship W2187738963A5050598747 @default.
- W2187738963 hasAuthorship W2187738963A5056712641 @default.
- W2187738963 hasConcept C105795698 @default.
- W2187738963 hasConcept C126322002 @default.
- W2187738963 hasConcept C194828623 @default.
- W2187738963 hasConcept C2777288759 @default.
- W2187738963 hasConcept C2779761222 @default.
- W2187738963 hasConcept C2780598303 @default.
- W2187738963 hasConcept C3018694869 @default.
- W2187738963 hasConcept C33923547 @default.
- W2187738963 hasConcept C526584372 @default.
- W2187738963 hasConcept C71924100 @default.
- W2187738963 hasConceptScore W2187738963C105795698 @default.
- W2187738963 hasConceptScore W2187738963C126322002 @default.
- W2187738963 hasConceptScore W2187738963C194828623 @default.
- W2187738963 hasConceptScore W2187738963C2777288759 @default.
- W2187738963 hasConceptScore W2187738963C2779761222 @default.
- W2187738963 hasConceptScore W2187738963C2780598303 @default.
- W2187738963 hasConceptScore W2187738963C3018694869 @default.
- W2187738963 hasConceptScore W2187738963C33923547 @default.
- W2187738963 hasConceptScore W2187738963C526584372 @default.
- W2187738963 hasConceptScore W2187738963C71924100 @default.
- W2187738963 hasIssue "11" @default.
- W2187738963 hasLocation W21877389631 @default.
- W2187738963 hasOpenAccess W2187738963 @default.
- W2187738963 hasPrimaryLocation W21877389631 @default.
- W2187738963 hasRelatedWork W1972203242 @default.
- W2187738963 hasRelatedWork W2062392398 @default.
- W2187738963 hasRelatedWork W2113533736 @default.
- W2187738963 hasRelatedWork W2187738963 @default.
- W2187738963 hasRelatedWork W2329860702 @default.
- W2187738963 hasRelatedWork W2358704748 @default.
- W2187738963 hasRelatedWork W2531261768 @default.
- W2187738963 hasRelatedWork W3019168892 @default.
- W2187738963 hasRelatedWork W3146514875 @default.
- W2187738963 hasRelatedWork W4242814225 @default.
- W2187738963 hasVolume "41" @default.
- W2187738963 isParatext "false" @default.
- W2187738963 isRetracted "false" @default.
- W2187738963 magId "2187738963" @default.
- W2187738963 workType "article" @default.